Study on Nivolumab and Cabozantinib Compared to Sunitinib for Untreated Advanced or Metastatic Kidney Cancer

Inclusion Criteria

• Have a confirmed diagnosis of renal cell carcinoma (RCC) with clear-cell features, which may also include sarcomatoid features.
• Have advanced kidney cancer that cannot be treated with surgery or radiation, or cancer that has spread to other parts of the body (Stage IV).
• Have not received any prior systemic treatment for kidney cancer, except if you had one previous treatment after surgery that did not include drugs targeting VEGF or its receptors, and if the cancer returned at least 6 months after the last dose of that treatment.

Exclusion Criteria

• Have active cancer that has spread to the brain or central nervous system.
• Have any active or suspected autoimmune disease.
• Require treatment with corticosteroids (more than 10 mg of prednisone daily) or other immunosuppressive drugs within 14 days before starting the study.
• Have received a live vaccine within 30 days before starting the study.

Other specific criteria may apply.